Oncotarget 2014-02-28

Engineered repressors are potent inhibitors of androgen receptor activity.

Greg N Brooke, Sue M Powell, Derek N Lavery, Jonathan Waxman, Laki Buluwela, Simak Ali, Charlotte L Bevan

Index: Oncotarget 5(4) , 959-69, (2014)

Full Text: HTML

Abstract

Prostate cancer growth is dependent upon the Androgen Receptor (AR) pathway, hence therapies for this disease often target this signalling axis. Such therapies are successful in the majority of patients but invariably fail after a median of 2 years and tumours progress to a castrate resistant stage (CRPC). Much evidence exists to suggest that the AR remains key to CRPC growth and hence remains a valid therapeutic target. Here we describe a novel method to inhibit AR activity, consisting of an interaction motif, that binds to the AR ligand-binding domain, fused to repression domains. These 'engineered repressors' are potent inhibitors of AR activity and prostate cancer cell growth and importantly inhibit the AR under circumstances in which conventional therapies would be predicted to fail, such as AR mutation and altered cofactor levels.